肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗

2021-09-10 中国肿瘤科相关专家小组（统称） Transl Lung Cancer Res

非小细胞肺癌肺癌

肺癌的治疗是肿瘤学领域的主要挑战之一，极早期非小细胞肺癌（NSCLC）可通过手术治愈。不过越有50%以上接受手术治疗的NSCLC患者会在5年内复发。

中文标题：

2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗

英文标题：

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

发布机构：

中国肿瘤科相关专家小组（统称）

发布日期：

2021-09-10

简要介绍：

肺癌的治疗是肿瘤学领域的主要挑战之一，极早期非小细胞肺癌（NSCLC）可通过手术治愈。不过越有50%以上接受手术治疗的NSCLC患者会在5年内复发。本文主要针对局部晚期非小细胞肺癌围术期免疫治疗提供共识指导。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b30ad1c0022558bd, title=2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗, enTitle=Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer, guiderFrom=Transl Lung Cancer Res, authorId=0, author=, summary=肺癌的治疗是肿瘤学领域的主要挑战之一，极早期非小细胞肺癌（NSCLC）可通过手术治愈。不过越有50%以上接受手术治疗的NSCLC患者会在5年内复发。, cover=https://img.medsci.cn/2021116/1636175756651_5579292.jpg, journalId=0, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Fri Sep 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">肺癌的治疗是肿瘤学领域的主要挑战之一，极早期非小细胞肺癌（NSCLC）可通过手术治愈。不过越有50%以上接受手术治疗的NSCLC患者会在5年内复发。本文主要针对局部晚期非小细胞肺癌围术期免疫治疗提供共识指导。</span></p>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌), TagDto(tagId=428, tagName=肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=276, guiderKeyword=非小细胞肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3055, appHits=189, showAppHits=0, pcHits=739, showPcHits=2865, likes=2, shares=26, comments=6, approvalStatus=1, publishedTime=Tue Nov 16 23:57:01 CST 2021, publishedTimeString=2021-09-10, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sat Nov 06 13:20:27 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 13:43:07 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗.pdf)])
2021专家共识：局部晚期非小细胞肺癌围术期免疫治疗.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1215592, encodeId=2a91121559220, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36542253479, createdName=zhoulang25, createdTime=Fri Apr 29 14:14:53 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193789, encodeId=b9a41193e8999, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2b14694211, createdName=99743925, createdTime=Tue Feb 15 22:12:11 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068228, encodeId=d29b106822857, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Nov 08 20:07:39 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068117, encodeId=327f106811e81, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:59:39 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2022-04-29 zhoulang25

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1215592, encodeId=2a91121559220, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36542253479, createdName=zhoulang25, createdTime=Fri Apr 29 14:14:53 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193789, encodeId=b9a41193e8999, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2b14694211, createdName=99743925, createdTime=Tue Feb 15 22:12:11 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068228, encodeId=d29b106822857, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Nov 08 20:07:39 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068117, encodeId=327f106811e81, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:59:39 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2022-02-15 99743925

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1215592, encodeId=2a91121559220, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36542253479, createdName=zhoulang25, createdTime=Fri Apr 29 14:14:53 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193789, encodeId=b9a41193e8999, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2b14694211, createdName=99743925, createdTime=Tue Feb 15 22:12:11 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068228, encodeId=d29b106822857, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Nov 08 20:07:39 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068117, encodeId=327f106811e81, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:59:39 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 JZ Yang

    感谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1215592, encodeId=2a91121559220, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36542253479, createdName=zhoulang25, createdTime=Fri Apr 29 14:14:53 CST 2022, time=2022-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193789, encodeId=b9a41193e8999, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2b14694211, createdName=99743925, createdTime=Tue Feb 15 22:12:11 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068228, encodeId=d29b106822857, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Mon Nov 08 20:07:39 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1068117, encodeId=327f106811e81, content=非常好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f3dd1885795, createdName=ms1812733236525890, createdTime=Mon Nov 08 13:59:39 CST 2021, time=2021-11-08, status=1, ipAttribution=)]
    2021-11-08 ms1812733236525890

    非常好

    0

相关指南

非小细胞肺癌分子残留病灶专家共识

中国抗癌协会肺癌专业委员会 · 2021-06-30

老年非小细胞肺癌患者的免疫治疗：青年国际老年肿瘤学会立场文件

国际老年肿瘤学会(SIOG,International Society of Geriatric Oncology) · 2021-11-01

FDA指导原则：批准非小细胞肺癌药物和生物制剂的临床试验终点

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2018-10-05

2021 SIR多学科立场声明：经皮消融治疗非小细胞肺癌和肺转移性疾病

介入放射学会(SIR,Society of Interventional Radiology) · 2021-08-25

非小细胞肺癌新辅助治疗疗效病理评估专家共识

国家肿瘤质控中心肺癌质控专家委员会 · 2021-09-08

非小细胞肺癌分子病理检测临床实践指南（2021版）

中华医学会病理学分会 · 2021-04-08

拓展阅读

ASCO指南：IV期非小细胞肺癌的维持治疗（2009）

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2009-12-20

2010CCO 晚期非小细胞肺癌一线全身化疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-01-01

2011 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识

中华医学会病理学分会 · 2010-01-01

2010ESMO临床实践指南：早期和局部晚期（非转移性）非小细胞肺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

2010ESMO临床实践指南：转移性非小细胞肺癌的诊断、治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

ASCO临时临床意见：考虑一线使用EGFR-TKI(表皮生长因子受体酪氨酸激酶抑制剂)的晚期非小细胞肺癌病人进行EGFR突变检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2011-04-11